LIFECORE BIOMEDICAL, INC. \DE\
For the period ended Feb 23, 2025. Filed Apr 3, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Feb 23, 2025 · Filed Apr 3, 2025
LFCR$6.36-0.6%Stored close · as of Nov 6, 2026
Contents
Condensed Consolidated Statements of Cash Flows for the Nine Months Ended February 23, 2025 and February 25, 2024
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited) (In thousands)
| Nine months ended | ||
|---|---|---|
| February 23,2025 | February 25,2024 | |
| Cash flows from operating activities: | ||
| Net (loss) income | $(37,570) | $19,096 |
| Adjustments to reconcile net income or loss to net cash used in operating activities: | ||
| Depreciation and amortization | 6,113 | 5,940 |
| Stock-based compensation | 8,343 | 4,603 |
| Non-cash interest expense, related party | 13,448 | 9,408 |
| Non-cash interest expense | 1,404 | 812 |
| Change in debt derivative liability, related party | (1,500) | (41,900) |
| Loss on sale or disposal of assets | 7,685 | 19 |
| Other, net | 193 | 1,706 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (602) | (2,711) |
| Contract assets | (2,081) | 213 |
| Inventories | 5,384 | 1,171 |
| Other assets | (1,236) | 1,984 |
| Accounts payable | (2,714) | (4,617) |
| Accrued expenses and other liabilities | (2,420) | (4,183) |
| Net cash used in operating activities | (5,553) | (8,459) |
| Cash flows from investing activities: | ||
| Purchases of property, plant, and equipment | (11,318) | (15,682) |
| Proceeds from sale of equipment | 7,000 | — |
| Net cash used in investing activities | (4,318) | (15,682) |
| Cash flows from financing activities: | ||
| Issuance of common stock, net of fees | 23,858 | — |
| Payments of debt principal | (699) | (482) |
| Payments for debt issuance costs | (435) | (124) |
| Proceeds from noncurrent customer deposit | — | 5,000 |
| Proceeds from exercise of stock options | — | 724 |
| Proceeds from finance lease incentive | 2,400 | — |
| (Repayments of) proceeds from revolving credit facility, net | (17,191) | 3,104 |
| Payments related to employee stock plans | (1,107) | (99) |
| Net cash provided by financing activities | 6,826 | 8,123 |
| Net decrease in cash and cash equivalents | (3,045) | (16,018) |
| Cash and cash equivalents, beginning of period | 8,462 | 19,091 |
| Cash and cash equivalents, end of period | $5,417 | $3,073 |
See accompanying notes to the condensed consolidated financial statements.
-6-
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.